Factor VIII inhibitors in two families with mild haemophilia A: Structural analysis of the mutations

Haemostasis

Volumn 30, Issue 5, 2000, Pages 268-279

  Knobe, Karin E ^a   Villoutreix, Bruno O ^d   Tengborn, Lilian I ^b   Petrini, Pia ^c   Ljung, Rolf C R ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Coagulation; Factor VIII; Haemophilia A; Inhibitor; Protein modelling; Structural analysis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CONFORMATIONAL TRANSITION; DISEASE PREDISPOSITION; GENE MUTATION; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; MALE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

EID: 0034467035     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054143     Document Type: Article

References (43)

1. The factor VIII structure and mutation resource site: HAMSTeRS version 4
2. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors
3. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
4. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
5. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
6. Haemophilia A: Mutation type determines risk of inhibitor formation
7. Possible linkage between the major histocompatibility complex and the immune response to factor VIII in classic haemophilia
8. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A
9. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII
10. Inhibitors in hemophilia patients: Current status and management
11. Prevalence of inhibitors in a population of 3435 hemophilia patients in France
12. Inhibitor of factor 8 in mild haemophilia
13. Inhibitors to factor VIII in a family with mild hemophilia: Molecular characterization and response to factor VIII and desmopressin
14. Factor VIII inhibitors in mild and moderate-severity haemophilia A
15. Inheritable molecular variants of moderate and mild hemophilia A
16. Structure of human factor VIII
17. Standardization of factor VIII. III. Establishment of a stable reference plasma for factor VIII-related activities
18. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase
19. Proceedings: A more uniform measurement of factor VIII inhibitors
20. Structure of the C2 domain of human factor VIII at 1.5 A resolution
21. The discoidin domain family revisited: New members from prokaryotes and a homology-based fold prediction
22. Enlarged representative set of protein structures
23. Protein S alters thhe active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study of topography
24. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation
25. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras
26. Clinical and laboratory manifestations of anti-factor V antibodies
27. A role for the C2 domain of factor VIII in binding to von Willebrand factor
28. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine
29. Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry
30. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site
31. The life cycle of coagulation factor VIII in view of its structure and function
32. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII
33. Massive factor VIII infusion in haemophiliac with factor VIII inhibitor, high responder
34. Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers
35. The missense mutation Arg593 → Cys is related to antibody formation in a patient with mild hemophilia A
36. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation
37. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
38. Intracellular accumulation of factor VIII induced by missense mutations Arg593→Cysand Asn618→Ser explains cross-reacting material-reduced haemophilia A
39. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor
40. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin
41. Epitope mapping of human factor VIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide
42. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII